You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
重藥控股(000950.SZ):重藥股份收到米拉貝隆緩釋片的藥品註冊證書
格隆匯 01-09 18:07

格隆匯1月9日丨重藥控股(000950.SZ)公佈,公司下屬控股子公司重慶醫藥(集團)股份有限公司(簡稱“重藥股份”)近日收到國家藥品監督管理局核准簽發的米拉貝隆緩釋片的《藥品註冊證書》。

米拉貝隆緩釋片由Astellas Pharma Europe B.V.研發,最早於2011年9月在日本上市銷售,商品名為Betanis®;2012年6月經美國FDA批准在美國上市,商品名為Myrbetriq®;2017年12月原研產品在中國上市,商品名為BETMIGA(貝坦利)。本品批准的適應症有成年膀胱過度活動症(OAB)患者尿急、尿頻和/或急迫性尿失禁的對症治療。

2023年8月,重藥股份就該藥品向國家藥監局提出註冊上市申請,並獲受理。截至公吿披露日,根據國家藥監局網站信息顯示,中國大陸境內已批准上市的米拉貝隆緩釋片企業有11家(含重藥股份)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account